Nicholas Restifo, MD

Nicholas Restifo, MD is a prominent figure in the field of cancer immunotherapy with an extensive background in research and development. He currently serves as the Chief Scientist and Head of R&D at Marble Therapeutics, a company based in Boston, Massachusetts.3

Career Highlights

Dr. Restifo has been pioneering new cell-based immunotherapies since 1989, including work on TIL (tumor-infiltrating lymphocytes), TCR-gene modified T cells, CAR-T cells, checkpoint blockade, and mechanisms of lymphodepletion.1 His career spans several decades and includes significant positions:

• Marble Therapeutics: Co-founder and Chief Scientist45
• National Institutes of Health: Principal Investigator for 30 years (July 1989 - July 2019)1
• Lyell Immunopharma: Executive Vice President of Research (July 2019 - February 2022)1
• RestifoPartners, LLC: Founder and CEO (February 2022 - Present)1

Education and Early Career

• Bachelor's degree in Natural Sciences from Johns Hopkins University (1979-1983)1
• Doctor of Medicine (MD) from New York University School of Medicine (1983-1987)1
• Postdoctoral Fellowship at Memorial Sloan Kettering Cancer Center (July 1988 - June 1989)1

Research Focus

Dr. Restifo is known as a "Cancer Immunotherapy Explorer".1 His work has been instrumental in advancing T cell-based immunotherapy, which has become a crucial area in cancer treatment.2 He has been involved in developing various innovative approaches to cancer immunotherapy throughout his career.

Current Work

At Marble Therapeutics, Dr. Restifo is likely applying his extensive experience in cancer immunotherapy to develop new cell-based treatments. His recent activities suggest a continued focus on advancing therapies for various cancers, including lung cancer.6